Beyond Selling Medicines by Xu, Ben
 
 
 
 
 
BEYOND SELLING MEDICINES 
 
by 
 
Ben Xu 
B. Sc. Hubei University 1997 
 
 
 
 
 
 
PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF 
THE REQUIREMENTS FOR THE DEGREE OF 
 
MASTER OF BUSINESS ADMINISTRATION 
 
 
 
In the Executive MBA Program 
of the 
Faculty 
of 
Business Administration 
 
 
 
© Ben Xu 2013 
 
SIMON FRASER UNIVERSITY 
Spring 2013 
 
 
 
All rights reserved. However, in accordance with the Copyright Act of Canada, this work 
may be reproduced, without authorization, under the conditions for Fair Dealing. 
Therefore, limited reproduction of this work for the purposes of private study, research, 
criticism, review and news reporting is likely to be in accordance with the law, 
particularly if cited appropriately. 
ii  
 
Approval 
 
 
 
Name:  Ben Xu 
 
 
Degree: Master of Business Administration 
 
 
Title of Project: Beyond Selling Medicines 
 
 
 
 
Supervisory Committee: 
 
 
 
 
 
 
 
Daniella Blettner 
Assistant Professor 
 
 
 
 
 
 
 
 
Colleen Collins 
Associate Professor 
 
 
 
 
 
 
Date Approved: 
 
 
 
3  
 
 
 
 
 
 
Executive Summary 
 
 
 
Overview 
 
 
Novartis is one of the largest pharmaceutical companies in the world, based in 
Switzerland, and operating in more than 140 countries worldwide. It is a leading 
pharmaceutical provider for diseases such as high blood pressure, diabetes, hypertension 
and cancer, to list a few. Its medicines reach more than 1.1 billion people each year. Our 
client is Novartis Brazil, a subsidiary operating in a fast growth emerging market. 
 
In order to build brand loyalty as well as to create additional revenue, Novartis 
Brazil has created a health program “Vale Mais Saude” (Valley Plus Health, VMS) which 
allow its members to enjoy price discount on prescription drugs and other potential 
benefits. The channel they currently use is mainly a call center which becomes a 
bottleneck because its limited capacity and expensive upkeep, which has resulted the 
program in a money losing position. Determined to put the program back on the winning 
track, Novartis is exploring new options to expand this program to increase its offerings 
to the user; potentially by partnering with other service providers to cross sell a wider 
range of products and services as the immediate step. The VMS program initially was 
probably only aiming at increase Novartis’ drug sales as well as building loyal user bases. 
However we see enormous opportunity to move Novartis’ market position beyond just 
selling medicines, but selling solutions meet various health care needs. The short term 
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goal for this long term vision is to collaborate with other service providers and package 
good products for the program users. 
 
Today there are around 250,000 users enrolled in the VMS program, who mostly 
have chronicle diseases and rely on Novartis medicines, and the number is still steadily 
growing. The program database contains all these users’ disease history and contact 
information, this information can be utilized to target specific user groups as well as the 
primary means to reach the users for marketing and communication purpose. Novartis 
delivers membership brochures to pharmacies where patients could pick up and register 
through the call centre. 
 
Novartis has been considering mainly two partnership programs Novartis is 
considering for additional revenue generation. One is to collaborate with banks to created 
co-branded credit cards to its members, who could get additional discount or loyalty 
reward, while Novartis could partial benefit from the interest on the credit card. The other 
is to affiliate with other health insurance providers to cross-sell their products and 
services and share the revenue or charge a referral fee. 
 
 
Novartis has already identified potential partners in banks and insurance 
 
providers, and scheduled meetings to request for proposal. These meetings are part of our 
project and team members from Brazil would attend these meetings with Novartis. Our 
task in this project is to collect proposals from these potential partners and analyse the 
feasibility for collaboration. If these partnership turned out to be successful both from user 
reception and revenue generation, Novartis can build on these partnership to solidify this 
program to sell beyond medicines. 
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Challenges 
 
 
Pharmaceutical industry is highly regulated, and there are many restrictions in 
terms of how company can market their products. Although it might vary from country to 
country, Brazil has recently tightened the rules on drug companies’ influence on 
physicians on how they prescribe medicines. Thus, it’s even more challenging for the 
drug companies to advertise additional products and services they are selling through 
partners. 
 
Other than regulation, reputation and brand image are also at risk when 
introducing new products and services, especially the ones from a 3rd party provider. The 
quality of the product and customer service might not be on par with Novartis’ standards. 
Physicians might also think twice to prescribe Novartis medicine to patients if that implies 
the patients would be exposed to other various unsolicited commercial offers 
from Novartis’ partners. 
 
 
The drug company itself is risk averse with so much R&D investment and 
people’s life at stake. The VMS program has not created the expected profit for a few 
years, but any internal discussion on broaden its offerings with outside vendors has been 
quietly resisted, especially from senior level. 
 
The unfavourable financial market conditions prompted Brazilian government to 
demand banks to lower consumer interest rate shortly after our project started. Interest 
rate has been traditionally very high in Brazil, and interest rate on credit card could be as 
high as 20% per month, comparing to the normal 20% per annum in North America. The 
new rate cut put a stop on all co-branded program for the banks while they reviewing the 
impact to their bottom line. For Novartis, it lost a potential revenue source, at least at the 
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time being, and needs to focus solely on insurance partnership program to generate 
additional revenue. 
 
However the scheduled meetings with insurance providers did not materialize on 
time, we did not receive any proposal until a couple weeks before our scheduled final 
presentation. This demonstrates that we are dealing with the real problem for the real 
client in the real world, where anything could change and we just need to adjust 
accordingly. 
 
 
 
 
Approach 
 
 
Our main goal is to evaluate the affiliate partnership with other providers to 
package value proposition solution and offer it to the registered users. We think it’s 
important to understand the pharmaceutical industry as a whole and Novartis’ long term 
vision so that we can answer questions like: How competitive is this industry? Does 
Novartis already have a competitive advantage over its competitors? As well as how 
strategic is the success of this program to Novartis? We did this through industry 
structural analysis, to gain a better understanding of the Novartis position in the industry 
and its strategy to support that position and future growth. 
 
A follow-up question to Novartis’ long term strategy is inherently related to the 
future and trend of the Pharmaceutical industry. Considering it’s a highly regulated 
industry, not one player has figured out how to grow the business beyond just making and 
selling molecules, how to penetrate into other health related products and services and 
create a full package or solution to end users. Diversification has obvious been a popular 
vii  
choice for some pharmaceutical companies, but the resulted different product lines do not 
deliver a congruent and holistic solution to end user. How to create a health package not 
only include medicine, but also diagnostic tool, physician consultation, dietary 
supplements and much more? More importantly, how to deliver such experience in the 
ever-evolving online channels? 
 
We tried to address these questions through a trend forecast analysis to understand 
the feasibility of this long term strategy, whether the technology will evolve to the degree 
to support both the channel and the product of such program? What other new innovation 
might be included into a holistic solution and how is the Pharmaceutical industry going to 
change the way people treat their illnesses? 
 
We also took a flexible approach in terms of the scope of this project. Since we 
 
are dealing with the real world problem, nothing is set in stone and things can change and 
often change fast. We devised a plan B in case any major projected milestone got stalled, 
and it did happen when we didn’t receive partner proposal months later than expected, 
the plan B essentially allow us to step back and look at the big picture, and assess the 
program from long term perspective. This way we can still deliver value to our clients 
even when the original plan falls apart. 
 
Since we are working as a virtual team with members from different country, we 
decided to have Brazilian team members to server as relationship managers, who keep in 
contact with client, join partner meetings and collect first-hand information. Other team 
member based in Canada, Mexico and the United States will serve as analysts to do 
research and analysis based on the data collected. Together the team would meet online 
weekly to brainstorm, exchange information and finalize the project. 
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Analysis and Recommendation 
 
 
Through our industry analysis, we found the pharmaceutical industry is highly 
competitive and profitable at the same time. It has extreme high barrier for new entrants 
due to the high cost of R&D to develop new drugs and length process to have them 
approved. Therefore, only selected few big players can play this game and competitions 
among them are fierce. Firms are constantly looking for a competitive advantage over 
others. 
 
Being in a profitable industry doesn’t automatically translate to competitiveness. 
Although Novartis is the leading patented medicine maker for a few popular diseases 
such as diabetes and high blood pressure, and positioned itself as focused diversified in 
areas such as generic drugs, eye care and consumer products[Figure 1], based on 
financial performance, it has not created a willingness to buy or low cost advantage 
[Figure 2]. This finding has vindicated the need to think outside of the box strategically, 
looking for lower cost might not get very far despite the low power of supplier, as most 
cost is incurred during R&D and approval phases which do not allow cutting corners; an 
innovative program which brings a total solution to patience in terms of medicine and 
related service and products, could definitely boost the willingness to buy and thus create 
a competitive advantage over others. 
 
The industry is projected to grow steadily overall, and rapidly in emerging 
markets. The global sales is expected to grow 60% to 1.6 $trillion in 2020 from about 1 
$trillion in 2011 [Figure 3]. Ground breaking technological innovations especially on 
genome and stem cell are accelerating in an unprecedented pace [Figure 4]. Information 
and manufacturing technologies are also lending themselves to better, leaner and quicker 
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delivery from research to cure. Instead of getting same medicine to everyone, it’ll be 
possible to have customized drugs tailored specifically to patient’s biological system to 
make it more effective. Personalized medicine is the future of this industry, though there 
need to be a good infrastructure to manage and deliver it to the end users. We think the 
program Novartis is trying to take to the next level could be well suited to lay down the 
ground work for an efficient network of channels to connect Pharmaceutical, physicians 
and other service providers to the end users. It’s an excellent strategic move to both get 
ahead of competition and embrace the future. 
 
In balance with the challenges the program is facing, we have devises a plan 
consists of gradual phases to build on its own success so that it won’t incur massive 
investment up front, and allow quick implementation to stay ahead of competition. 
 
Proposal 
 
 
Phase 1: 
 
 
• With minimum investment, leverage existing client base and partners’ channels to 
deliver additional products and services. 
 
• Focus on partnering with insurance providers only. 
 
 
• Create differentiated insurance plans with benefits related to health that would be 
attractive to current clients. 
 
• Profit generation by sharing revenue from insurance plans sales through existing 
customer contact channels. 
 
Phase 2: 
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• Partner with other products and services providers offering value-added products, 
such as fitness membership, eye care, and nutritional supplements. 
 
• Prepare customized packages based on each channel to be offered with discounts 
to target clients. 
 
• Receive a percentage of the sales made through the program. 
Phase 3: 
• Invest to expand and enhance current channels, especially online, in social media 
and mobile devices. 
 
• Partner with new service providers based on new channels. 
 
 
• Create reward/loyalty program to increase sales. 
 
 
• Grow the program client base. 
• Offer the benefits to prospects out of the client list. 
Benchmark 
 
 
Our benchmark is mainly at a business model level. We looked at Business to 
Business and Business to Consumer models and compared with other companies in 
different verticals. We think the two major areas Novartis could apply to VMS program 
are online advertising and direct sale, especially in the later phases when online channel 
becomes prominent. 
 
Online advertising for health related products and services on VMS’s web portal 
could garner additional revenues. 
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With more products offered in VMS, we could see its online channel become a 
specialized version of Amazon, a platform focused on consumer health care and lifestyle 
needs. The advantages of Amazon business model include: 
 
• Availability of demographic and behavioural data about customers allows direct 
marketing and personalized services. 
 
• Personalization enabled retailers to use dynamic pricing, whereby prices were 
changed based on demand (i.e., the value placed on the product or service by a 
target customer) or supply (e.g., product availability) conditions. 
 
• Receive cash from sales in a day, but only pay for inventory after 60 days. 
 
 
Novartis could also establish above advantages when it consolidates all its 
channels to Internet-based in the later phases, which is what we would recommend. 
 
Financial projection 
 
 
Based on a set of assumptions [Table 2], which are in line with the demographic 
of the users registered in VMS program, as well as going market conditions. We have 
projected the revenue and operational cost in the next 5 years [Table 3, 4] for phase1 
implementation. The key takeaways are: 
 
• Projected revenue will cover legacy base costs after 2.5 years 
 
 
• Strong revenue generation with over 16 million BRL net present value in 5 years 
 
 
• Total project net present value of about 60.3 million BRL in 5 years 
 
 
• Impressive sales units increase from 320,000 units to 2.1 million units. 
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We have also done a sensitivity analysis and identified 4 sensitivity pillars, they 
represent the key items to be monitored throughout the process because these items 
would have strong influence on the projected revenue. 
 
• Sales rate: This item has 24.9% impact on the project revenue in 5 years. The 
business case is assuming a sales rate of about 10%. 
 
• Sales rate (call center inbound): Sales rate for call center inbound is the second 
most sensitive item with 19.8% weight. 
 
• Offer rate (call center inbound): Offer rate for call center inbound contributes 
 
11.5%. 
 
 
• Churn: This item represents the customer early termination rate. The assumption 
in the model for this item is 2.5%. This item has a significant sensitivity factor of 
about -11.5%. 
 
There are other sensitivity factors that are also important; however the project 
management should focus on these four major items. We recommended developing 
monthly KPI reports to monitor the trend of these pillars to ensure project success. 
 
Final recommendation 
 
 
In terms of final recommendation for this project, it is not about choosing one 
insurance provider over another. These partners are not mutually exclusive, and on paper 
all 3 proposals from 3 insurance provider are quite similar in terms of the component and 
cost. Our recommendation comes in the form of the phased approached business model 
and accompanied analysis and projection, and we believe this model is feasible and will 
contribute to the long-term strategy – selling beyond medicines. 
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Figure 2 - Novartis has no competitive advantage based on its financial performance 
comparing to competitors 
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Figure 3 – Projected industry growth 
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Figure 4 - Cost projection for gene-sequencing  (Source: Roche Personalized Healthcare) 
 
 
 
 
 
 
Figure 5 – Historical cost structure for Amazon 
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Threat of Potential 
Entrants * 
High entry barrier due to: 
• Long lead time for drugs with high cost of R&D 
(Novartis invested $9.5B in R&D in 2011) 
• High investment in marketing (Novartis expenses with 
marketing and sales was $15B in 2011) 
• Strong regulation, varying in each country. 
Low - 
Moderate 
Power of Buyers • Loss of brand loyalty as medical practitioners are forced 
to become cost conscious and consider prescribing 
generic rather than brand drugs 
• Growth of managed care (and the information it 
provides) is expected to continue deteriorating the 
profitability of big pharmaceuticals regardless of the 
outcome of regulation 
Moderate - 
High 
Power of Substitutes • Cheap generics 
• Consumer suspicion of drugs leads to increasing use of 
alternative remedies 
• Biotechnology and combinational chemistry further 
reduce lead times to market 
Moderate - 
High 
Power of Suppliers • Global sourcing – low cost raw materials Low 
Competitive Rivalry * • High exit barrier: high cost of R&D 
• M&A to continue consolidation 
 
* Government is a complement: it affects the Rivalry and 
Potential Entrants with regulation 
High 
 
Table 1 – Porter’s five forces analysis for pharmaceutical industry 
18 
 
 
Inbound Sales - Convert  Offer 
Rate 
  Sales 
(units) 
Convertion 
rate income calls # of calls Offer Sales Rate 
 
New consumers 
 
25.000 
 
20% 
 
5.000 
 
10% 
 
500 
 
2,00% 
 
Customer support 
 
35.000 
 
20% 
 
7.000 
 
10% 
 
700 
 
2,00% 
 
Total 
 
60.000 
  
12.000 
  
1.200 
 
       Outbound Sales - Convert     
Assumptions 
  
New users in database  
 Database Opt 
in 
 
24.500 
 
100% 
   
  
1 
 
417 
 
2% 
 
Churn (monthly) 
 
2,5% 
 
  
2 
 
1.103 
 
5% 
 
PA Full cost 
 
8.000 
 
  
3 
 
882 
 
4% 
Avg. # of PA 
p.y. 
 
31 
 
  
4 
 
10.119 
 
41% 
 
Email 
 
0,01 
 
  
5 
 
2.254 
 
9% 
 
SMS 
 
0,12 
 
  
6 
 
7.301 
 
30% 
 
Direct Mail 
 
1,90 
 
  
7 
 
74 
 
0% 
 
VMS Margin 
 
20% 
 
  
8 (w/o 
permission) 
 
 
 
2.352 
 
 
 
10% 
  
Revenue 
(p/un.) 
 
VMS 
Revenue (p/u) 
     
Inbound 
 
20,00 
 
4,00 
 
Channel (interact) 
 
Offer Rate 
Sales 
Rate 
Conversio 
n Rate 
 
Outbound 
 
20,00 
 
4,00 
 
Email 
 
8% 
 
10% 
 
0,80% 
 
Cross Selling 
 
10,00 
 
2,00 
SMS   0,00%    
 
Direct Mail 
 
10% 
 
10% 
 
1,00% 
Benchmark 
(source:  Metlife 
and 
Ace) 
 
Phone 30% 10% 3,00%    
    Active 
Convertion % 
3%- 
3,5% 
 
Outbound Sales - Convert    Active PA (# of 
contacts) 
 
2.500 
 
existing users in database  
  
Database Opt 
in 
 
1.500.00 
0 
 
 
 
100% 
 
Receptive PA (# 
of contacts) 
 
 
 
1.300 
 
 1  2% Receptive 8%  
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  25.500  Convertion rate 
% 
  
  
2 
 
67.500 
 
5% 
   
  
3 
 
54.000 
 
4% 
   
  
4 
 
619.500 
 
41% 
   
  
5 
 
138.000 
 
9% 
   
  
6 
 
447.000 
 
30% 
   
  
7 
 
4.500 
 
0% 
   
 8 (w/o 
permission) 
 
144.000 
 
10% 
   
        
 
Table 2 – Financial  model assumptions 
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Revenue Year 1 Year 2 Year 3 Year 4 Year 5 Total 5 yrs 
Total Sales unit 319.965 1.096.740 1.534.568 1.858.497 2.110.000 6.919.770 
Total Revenue R$ 6.157.247 19.145.877 24.192.242 27.691.989 30.399.228 107.586.583 
       VMS Results       
Revenue R$ (inbound) 342.132 856.144 1.235.485 1.515.438 1.722.042 5.671.241 
Revenue R$ (outbound 
new) 
 
137.839 
 
511.144 
 
804.879 
 
1.021.656 
 
1.181.636 
 
3.657.154 
Revenue R$ (outbound 
legacy) 
 
703.068 
 
1.904.102 
 
1.498.260 
 
1.105.713 
 
816.014 
 
6.027.157 
Revenue R$ (cross 
selling) 
 
48.411 
 
557.785 
 
1.299.824 
 
1.895.591 
 
2.360.153 
 
6.161.765 
Total VMS Revenue 
R$ 
 
1.231.449 
 
3.829.175 
 
4.838.448 
 
5.538.398 
 
6.079.846 
 
21.517.317 
 
Table 3 – Revenue projection in 5 years 
 
 
 
 
 
 
 
 
Operational Cost Year 1 Year 2 Year 3 Year 4 Year 5 Total 5 yrs 
Inbound       
# Total Inbound Costs 654.545 654.545 654.545 654.545 654.545 3.272.727 
Outbound (New)       
Total Outbound New 
Costs 
 
1.358.787 
 
1.358.787 
 
1.358.787 
 
1.358.787 
 
1.358.787 
 
6.793.937 
Outbound (Legacy)       
Total Outbound 
Legacy Costs 
 
6.929.354 
     
6.929.354 
Cross Selling       
# Total Cross selling 
Costs 
 
253.579 
 
1.229.945 
 
1.449.275 
 
1.495.723 
 
1.530.001 
 
5.958.523 
 
Table 4 – Operation cost projection in 5 years 
